Research and Reports in Urology, 2013 Raymond T Lee,1 Mitchell Bamberger,2 Pamela Ellsworth31University of Massachusetts Medical School, 2UMass Memorial Medical Center, University of Massachusetts Medical School, Worcester, MA, 3Division of Urology/Surgery, Warren Alpert Medical School of ...
Lee RT, Bamberger M, Ellsworth P
doaj +1 more source
Efficacy and Safety of Mirabegron in Males with Overactive Bladder and Lower Urinary Tract Symptoms: Analysis from an Integrated Database [PDF]
European Urology Open ScienceBackground and objective: Several phase 2–4 studies have investigated mirabegron for treating patients with overactive bladder (OAB). The objective of this study was to evaluate the efficacy and safety of mirabegron in adult male OAB patients with or ...
Farid Abdul Hadi +4 more
doaj +2 more sources
Mirabegron: the review of current knowledge of safety and efficacy in the relief of overactive bladder symptoms [PDF]
Journal of Education, Health and Sport, 2018 Mirabegron has been registered as the first strong and selective agonist of the β3 receptor. It is currently used for relief of symptoms of overactive bladder (OAB).
Tomasz Aleksiewicz +5 more
doaj +4 more sources
Profile of mirabegron in the treatment of overactive bladder: place in therapy
Drug Design, Development and Therapy, 2017 Ala’a Sharaf, Hashim Hashim Female and Functional Urology Unit, Bristol Urological Institute, Bristol, UK Abstract: Mirabegron is a relatively new drug introduced to treat overactive bladder syndrome.
Sharaf A, Hashim H
doaj +1 more source
Mirabegron treatment reduces myofibroblasts and CXCR2 expression in adipose tissue in obesity [PDF]
Molecular MedicineBackground Treatment with the β3-adrenergic receptor (AR) agonist mirabegron improves insulin sensitivity β, cell function, and glucose tolerance in individuals with obesity, without weight loss or a change in brown adipose tissue (BAT) (Finlin et al, J ...
Brian S. Finlin +5 more
doaj +2 more sources
Mirabegron for accelerating passage of 6–10 mm distal ureteral stones after extracorporeal shock wave lithotripsy: a retrospective cohort study [PDF]
BMC UrologyObjective To evaluate the clinical outcomes associated with mirabegron as adjunctive medical expulsive therapy after extracorporeal shock wave lithotripsy (ESWL) for 6–10 mm distal ureteral stones. Methods We retrospectively analyzed patients with distal
Xiang Hu +4 more
doaj +2 more sources
Beni-Suef University Journal of Basic and Applied SciencesBackground Inserting ureteral stents is a routine intervention that often results in problems. The cornerstone for treating stent-related symptoms is pharmacological therapy.
Akrm A. Elmarakbi +3 more
doaj +2 more sources
Off-Target Effects of Mirabegron on Muscarinic Receptors
Future PharmacologyOlder adults with multiple diseases are likely to be prescribed multiple medications including anticholinergic agents, which are frequently prescribed to manage conditions such as overactive bladder and chronic obstructive pulmonary disease and Parkinson’
Shizuo Yamada +3 more
doaj +2 more sources
Mirabegron for intramural ureteral stones with vesical irritability: a prospective study [PDF]
Frontiers in PharmacologyObjectiveTo assess the efficacy of mirabegron in patients with intramural ureteral stones (6–10 mm).MethodsWe prospectively randomized 92 patients with intramural ureteral stones into two groups.
Mengjun Dai, Yuhang She, Hao Wang
doaj +2 more sources
Mirabegron exhibits antibacterial and Immunomodulatory activities demonstrated by in vitro and in vivo studies [PDF]
Scientific ReportsMirabegron is a beta 3-adrenoceptor agonist that can help with incontinence, dysuria, and bladder overactivity. It alleviates the symptoms of prostate enlargement and urinary tract infections (UTIs) in the elderly.
Esraa A. Ahmed, Ahmed M. Abd-Eldayem
doaj +2 more sources